Loading company…
Riskpilot
← Back to search
Sign in
Get full access
NATTOPHARMA AS
AS
Active
Org 919864559
Etasje 05 Mustads Vei 1, 0283 Oslo
Manufacture of basic pharmaceutical products · NACE 2110
Est. 2017
0 employees
Watchlist
Share
Download PDF
Full Risika report
Overview
Financials
People & ownership
Related companies
Revenue 2021
NOK 3,2M
+1% vs 2020
EBITDA margin
8.0%
+113% vs 2020
Equity ratio
-464.0%
Financial strength
Net profit 2021
NOK -4M
+37% vs 2020
EBITDA — year on year
NOK millions
0M
0M
1M
1M
1M
-13M
2018
-5M
+62%
2019
-2M
+60%
2020
0M
+100%
2021
Key figures
Annual report 2021
Revenue
NOK 3,2M
+1%
EBITDA
NOK 258K
+113%
Net profit
NOK -4M
+37%
Total assets
NOK 10,1M
-28%
Equity
NOK -47M
-9%
Employees
0
—
Company information
Legal name
NATTOPHARMA AS
Org number
919864559
Legal form
Aksjeselskap
NACE code
2110 · Manufacture of basic pharmaceutical products
Founded
7. november 2017
Share capital
NOK 554 066 900
Employees
0
VAT registered
No
Audit selected
No
Last report
2021-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Direkte og indirekte å utvikle, distribuere og selge farmasøytiske produkter samt tilknyttede tjenester til dette.
Contact
Address
Etasje 05 Mustads Vei 1, 0283 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Manufacture of basic pharmaceutical products
Companies in Oslo
All Norway companies
Revenue
NOK millions
0M
1M
2M
3M
3M
1M
2018
2M
2019
3M
2020
3M
2021
EBITDA
NOK millions
0M
0M
1M
1M
1M
-13M
2018
-5M
2019
-2M
2020
0M
2021
Income statement
NOK thousands
Item
2018
2019
2020
2021
Revenue
1 457
1 816
3 208
3 242
Staff expenses
−0
−0
−0
−0
EBITDA
−12 985
−5 287
−2 030
258
Depreciation & amort.
−11 792
−42 266
−1 635
−1 684
EBIT
−24 778
−47 553
−3 664
−1 426
Net financials
−3 119
−2 612
−2 636
−2 540
Profit before tax
−27 897
−50 164
−6 301
−3 966
Tax
−0
−0
−0
−0
Net profit
−27 897
−50 164
−6 301
−3 966
Balance sheet
NOK thousands
Item
2018
2019
2020
2021
Total assets
60 635
14 758
14 047
10 129
Equity
9 494
−40 733
−43 033
−46 999
Long-term debt
38 354
53 633
54 098
56 548
Short-term debt
12 787
1 858
2 983
581
Total debt
51 142
55 491
57 080
57 129
Financial ratios
5-year trend
EBITDA margin
8.0%
This company
15.8%
Market median
-49% vs market
2018
2021
Equity ratio
-464.0%
This company
38.2%
Market median
-1315% vs market
2018
2021
Return on equity
-396600000.0%
This company
18.4%
Market median
-2155434883% vs market
2018
2021
Net profit margin
-122.3%
This company
8.1%
Market median
-1610% vs market
2018
2021
Asset turnover
0.32×
This company
1.12×
Market median
-71% vs market
2018
2021
Debt / equity
1.22×
This company
0.62×
Market median
-97% vs market
2018
2021
Annual reports & filings
Annual report 2021
Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
View
PDF
Annual report 2020
Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
View
PDF
Annual report 2019
Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
View
PDF
Annual report 2018
Filed via Brønnøysundsregistrene · Period 2017-10-27 – 2018-12-31
View
PDF
Management
Actively employed in the business
No data on file.
Board of directors
Non-executive oversight
Name
Role
Member since
Age
Other directorships
RS
Robert Schrama
Board of Directors
2022
—
—
MG
Marc Georges Claude Philouze
Chairman
2022
—
—
KR
Kjetil Ramsøy
Chairman
2020
—
—
Shareholders
As of last annual report
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
No registered parent or subsidiaries
Board network connections
Board members of NATTOPHARMA AS also hold positions in
0
other companies.
Person
Role here
Other companies
Robert Schrama
Board of Directors
0 companies
Marc Georges Claude Philouze
Chairman
0 companies
Kjetil Ramsøy
Chairman
0 companies